Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the ...(cam growth continues to be at the top of...),Health

Date:5/12/2008

cam growth continues to be at the top of the category and growth of Zicam products at retail was higher than our factory shipment growth. For the 12 weeks ended March 23, 2008, retail sales (three-outlet syndicated scanner data, which does not include our largest customer Wal-Mart) of Zicam products increased approximately 25%, while the total cough/cold category increased approximately 12% compared to the prior year. This growth resulted in Zicam products attaining a 3.6% dollar share of the category, versus 3.2% in the comparable period a year ago. For the entire cold season, as measured by the 24 weeks ended March 23, 2008, retail sales of Zicam products increased approximately 8%, while the total cough/cold category increased approximately 4% compared to the prior year."

Mr. Johnson continued, "During the cold season, we initiated new marketing programs that focused on our unique swab delivery Cold Remedy product. Early indications of the new programs reflect strong success in the concept, resulting in high retail sales pull through. During fiscal 2008 retail sales of Zicam Cold Remedy Swabs(TM) increased over 20% and, during our fiscal fourth quarter, retail sales of swab products were up over 50%. Additionally, we continued to see robust growth from our oral delivery Cold Remedy products. We expect to continue focusing our marketing on the unique attributes of Zicam products to foster future growth. Initial shipments of our Xcid(TM) antacid occurred at the end of fiscal 2008 to a single retailer. Launching a new brand takes time and we anticipate marketing efforts focused on Xcid to begin in the current quarter, including a large sampling effort."

"In fiscal 2009, we will focus on growing our brands, increasing consumer awareness, and improving our operating income margin. In fiscal 2008, operating income margin increased to 16%, compared to 10% for the twelve months ended March 31, 2007. We believe there are opportunities to increase operating i
'/>"/>

SOURCE Matrixx Initiatives, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
2. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
4. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
6. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
7. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
10. CryoCath Announces Fiscal 2008 Second Quarter Results
11. OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY